Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | TOURMALINE-AL1: ixazomib for AL amyloidosis

Angela Dispenzieri • 31 May 2020
Amyloidosis Rare Diseases Cyclophosphamide Dexamethasone Ixazomib Lenalidomide Melphalan Thalidomide
TOURMALINE-AL1

Angela Dispenzieri, MD, of the Mayo Clinic College of Medicine, Rochester, MN, touches on the results of the TOURMALINE-AL1 study (NCT01659658), a randomized study evaluating ixazomib and dexamethasone in the relapsed/refractory amyloid light-chain (AL) amyloidosis setting. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Angela Dispenzieri

1:53
Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria
Angela Dispenzieri • 6 Sep 2023
2:30
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
Angela Dispenzieri • 6 Sep 2023
1:42
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease
Angela Dispenzieri • 6 Sep 2023
1:57
Rationale behind the watch and wait strategy in smoldering myeloma
Angela Dispenzieri • 6 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals